Vertex struck a milestone deal with NHS England to make its cutting-edge cystic fibrosis drug ALYFTREK available to eligible ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Penserra Capital Management significantly reduced its stake in Vertex Pharmaceuticals, dropping 81% of its shares in the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The stock's fall snapped a three-day winning streak.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Get the latest news on Vertex Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on VRTX performance ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...